China-based Everest Medicines (HKG: 1952) has announced the signing of a memorandum of understanding (MoU) with Sinopharm Group Co., Ltd. The partnership aims to capitalize on Sinopharm’s supply chain service advantages in distribution, access, and retailing for Everest’s listed products within mainland China. The collaboration will also explore new product imports and novel business cooperation opportunities, although no financial details were disclosed.
Leveraging Sinopharm’s Supply Chain for Everest’s Products
Everest Medicines, with its two approved products, Trodelvy (sacituzumab govitecan), a TROP-2 targeted antibody drug conjugate (ADC), and Xerava (eravacycline), an anti-infection drug, seeks to enhance its market presence in China. Trodelvy, approved in China in March 2023, is being prepared for commercial launch in the mainland market.
Future Product Launches and Pipeline Expansion
The company plans to launch three more products in China within the next two years, reflecting its commitment to expanding access to innovative treatments. These include Nefecon (targeted-release formulation-budesonide), an IgA nephropathy therapy expected to win approval later this year, cefepime, and taniborbactam with an NDA filing for complicated urinary tract infection expected within this year. Additionally, etrasimod, an oral S1P modulator that has shown positive Phase III clinical results, is part of Everest’s pipeline.-Fineline Info & Tech
